2025-07-16
The registration certificate of the Class Ⅲ medical device, Poly-L-lactic Acid Microparticle Filler Injection (the “Product”), has been approved by the National Medical Products Administration of China (NMPA), which marks a significant milestone for Xihong Biopharma in the regenerative product field, further expanding its consumer healthcare product portfolio.
